Follow our progress.

Milestones in our journey to reinvent genetic testing.

Back to full list

Press Releases

Joining forces with Locus Development

Joining forces with Locus Development

August 08, 2012

Genomic Health Announces Second Quarter 2012 Financial Results and Business Progress

  • Product Revenue Increased 13% Compared with Prior Year 
  • Delivered Net Income of $1.8 Million 
  • Began Offering Oncotype DX® Colon Cancer Test for Stage III Patients 
  • Combined Invitae with Locus Development to Create Independent Genetics Company 
  • Conference Call Today at 4:30 p.m. ET 

REDWOOD CITY, Calif., Aug. 8, 2012 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June ...

Read more

Company Formation

Company Formation

February 06, 2012

Genomic Health Announces Formation of New Genetics Subsidiary

REDWOOD CITY, Calif., Feb. 6, 2012 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced plans to establish a wholly owned subsidiary with the goal of improving the quality of diagnosis, communication and support for millions of patients and their families faced with common and rare genetic conditions.   The subsidiary is expected to be established by March 1, 2012 and provide its first commercial service in 2013.  The new venture will be led ...

Read more

Invitae’s Mission

Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice in order to improve healthcare for billions of people. There are three stages to Invitae’s business model:

  1. Make genetic testing more affordable and accessible than ever before.
  2. Build a secure and trusted genome management infrastructure with which we help individuals manage their own genetic information over the course of their life.
  3. Design a genome network, a global community for sharing genetic information to advance science and medicine and allow patients, doctors and organizations to connect around genetic conditions.

Invitae’s four core principles

  1. Patients should own and control their own genetic information.
  2. Healthcare professionals are fundamental in ordering and interpreting genetic information.
  3. Driving down the price of genetic information will increase that information’s clinical and personal utility.
  4. Genetic information is more valuable when shared.

About Invitae

Invitae Corporation’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising hundreds of genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas.

For more information, visit out website at and follow us on Twitter: @invitae and @invitaeIR